Amylin is a hormone produced by the same cells in your pancreas that make insulin. It plays a central role in controlling blood sugar after meals by slowing digestion, curbing appetite, and keeping other hormones in check. Though far less famous than insulin, amylin is essential for normal glucose regulation, and its dysfunction is closely tied to both type 1 and type 2 diabetes.
Where Amylin Comes From
Amylin is made by the beta cells of the pancreas, the same cells responsible for insulin. After production, amylin is packaged together with insulin inside tiny storage compartments called secretory granules. When you eat and blood sugar rises, these granules release both hormones into the bloodstream at the same time. The two are co-secreted in a fixed ratio: for roughly every 100 molecules of insulin released, about 1 molecule of amylin comes with it.
This tight pairing means amylin levels closely mirror insulin levels throughout the day. They rise after meals and fall during fasting. Because amylin depends on functioning beta cells, anything that damages or destroys those cells, like the autoimmune attack in type 1 diabetes or the progressive burnout seen in advanced type 2 diabetes, reduces amylin output alongside insulin.
What Amylin Does After a Meal
Amylin’s main job is to fine-tune blood sugar control during and after eating. It does this through three distinct mechanisms that work together.
First, amylin slows gastric emptying, the rate at which food leaves your stomach and enters the small intestine. This is a powerful effect. In animal studies, amylin reduced the movement of food out of the stomach by as much as 84% compared to controls. By keeping food in the stomach longer, amylin prevents a rapid flood of glucose into the bloodstream after a meal.
Second, amylin suppresses glucagon, a hormone released by different pancreatic cells (alpha cells) that tells the liver to release stored glucose. After you eat, you already have incoming glucose from food, so you don’t need the liver adding more. Amylin blocks that signal. Without this brake, the liver would continue dumping glucose into the blood even when levels are already rising from a meal, which is exactly what happens in people with diabetes who lack amylin.
Third, amylin promotes satiety. It acts on areas of the brain involved in appetite and reward, including regions that influence how much you eat per meal and how motivated you feel to keep eating. Research in rats has shown that activating amylin receptors in the brain’s reward center reduces both regular food intake and the drive to consume sugary solutions, and this happens through smaller meal sizes rather than nausea or sedation.
Amylin’s Role in Diabetes
In type 1 diabetes, the immune system destroys beta cells, which eliminates the source of both insulin and amylin. People with type 1 diabetes are almost entirely amylin-deficient. This deficiency contributes to the difficulty of managing post-meal blood sugar with insulin alone. Without amylin slowing digestion and suppressing glucagon, glucose from food hits the bloodstream fast and hard, creating the sharp spikes that are so difficult to cover with injected insulin.
Type 2 diabetes has a more complex relationship with amylin. In the early stages, when the body is resistant to insulin, beta cells compensate by pumping out more insulin and more amylin. This period of overproduction, called hyperamylinemia, actually precedes the formal diagnosis of type 2 diabetes. Over time, however, the beta cells wear out. In advanced type 2 diabetes, secretion of both amylin and insulin drops significantly, and the beta cells lose their ability to respond to glucose altogether.
How Amylin Damages the Pancreas
One of amylin’s most destructive properties emerges when it is overproduced. Unlike many hormones, human amylin has a tendency to misfold and clump together into sticky aggregates called amyloid deposits. These deposits accumulate in and around the beta cells of the pancreas and are found in the majority of people with type 2 diabetes at autopsy.
The damage appears to come primarily from an intermediate stage of clumping. Before amylin forms its final fibrous deposits, it passes through a phase as small, soluble clumps called oligomers. These oligomers are more toxic to beta cells than the finished fibrils. They punch holes in cell membranes, trigger oxidative stress, overwhelm the cell’s protein-recycling machinery, and ultimately push beta cells into programmed cell death. The result is a vicious cycle: as beta cells die, the remaining cells work harder, produce more amylin, and accelerate the formation of toxic aggregates. This progressive loss of beta cell mass is a hallmark of type 2 diabetes progression.
Synthetic Amylin as a Treatment
Because people with diabetes lack adequate amylin, researchers developed a synthetic version called pramlintide (brand name Symlin). It is FDA-approved for people with type 1 or type 2 diabetes who use mealtime insulin but haven’t achieved adequate blood sugar control with insulin alone.
Pramlintide is injected under the skin of the abdomen or thigh just before major meals. For type 2 diabetes, the starting dose is 60 mcg per meal, which can be increased to 120 mcg if tolerated. For type 1 diabetes, the starting dose is lower (15 mcg) and is gradually increased in small steps up to 60 mcg. When starting pramlintide, mealtime insulin doses are cut by 50% to avoid dangerously low blood sugar, then adjusted based on monitoring.
Nausea is the most common side effect, which is why dose increases are spaced at least three days apart. Because pramlintide works partly by slowing stomach emptying, it is not appropriate for people who already have gastroparesis, a condition where the stomach empties too slowly on its own. This is particularly relevant because gastroparesis is itself a common complication of long-standing diabetes.
Amylin-Based Therapies for Obesity
Amylin’s appetite-suppressing effects have made it an attractive target for weight loss drugs. The most notable development is cagrilintide, a long-acting amylin analog that can be injected once weekly rather than before every meal. In clinical trials, cagrilintide has been combined with semaglutide (a GLP-1 drug already widely used for weight loss) in a combination called CagriSema. The REDEFINE 1 trial, published in the New England Journal of Medicine, tested this combination in adults with overweight or obesity who did not have diabetes.
The rationale for combining the two is that amylin and GLP-1 drugs suppress appetite through partially different brain pathways. By targeting both systems simultaneously, the combination may produce greater weight loss than either drug alone. This dual-hormone approach represents a shift in how researchers think about weight management, moving from single-target drugs toward therapies that mimic the body’s own layered system of appetite control.